Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Amala Ambati

Rheumatology Sylvania, OH Medical Doctor

NPI 1144758665 CMS profile 11451701

5700 Monroe St Unit 202, Sylvania, OH 43560

Open in the dashboard

General payments

$2,873

136 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amala Ambati of Sylvania, OH is reported in the CMS Open Payments database as having received $2,873 across 136 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,462 68
2024 General $1,234 63
2023 General $177 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amala Ambati
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Amala Ambati were reported at $1,462. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Amala Ambati Rheumatology median Middle half National median
2019 $0 $744 $153–$2,687 $163
2020 $0 $462 $98–$2,027 $114
2021 $0 $531 $101–$2,153 $132
2022 $0 $627 $125–$2,303 $149
2023 $177 $741 $145–$2,524 $160
2024 $1,234 $830 $166–$2,660 $164
2025 $1,462 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $1,197 68 payments
  2. Amgen Inc. $703 37 payments
  3. Janssen Biotech, Inc. $635 17 payments
  4. AstraZeneca Pharmaceuticals LP $79 3 payments
  5. UCB, Inc. $55 2 payments
  6. Aurinia Pharma U.S., Inc. $51 2 payments
  7. E.R. Squibb & Sons, L.L.C. $39 2 payments
  8. GlaxoSmithKline, LLC. $38 2 payments
  9. Lilly USA, LLC $28 1 payment
  10. Genzyme Corporation $24 1 payment
  11. Other $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $2,649 132 payments
  2. Education $224 4 payments
Products named General payments · program years 2023–2025
  1. RINVOQ $876 46 payments
  2. TREMFYA $635 17 payments
  3. TAVNEOS $573 26 payments
  4. SKYRIZI Immunology $176 14 payments
  5. SIMPONI ARIA $145 1 payment
  6. SKYRIZI Immunology $145 8 payments
  7. KRYSTEXXA $57 8 payments
  8. LUPKYNIS $51 2 payments
  9. SAPHNELO $51 2 payments
  10. Enbrel $50 2 payments
  11. Other $312 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

637

Median for Rheumatology: 1,511

Drug cost

$462,442

Median for Rheumatology: $1,139,948

Branded share of claims

30.8%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 29 $200,670
Enbrel Sureclick Etanercept Brand 25 $182,939
Xeljanz Tofacitinib Citrate Brand 13 $66,499
Hydroxychloroquine Sulfate Generic 84 $4,170
Methotrexate Methotrexate Sodium Brand 129 $2,524
Prednisone Generic 215 $1,817
Colchicine Generic 12 $1,799
Allopurinol Generic 41 $655
Diclofenac Sodium Generic 12 $446
Duloxetine Hcl Generic 15 $435

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$23,915

Medicare's payments for the services billed

Medicare patients

121

Average age 71

Services billed

243

94 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 67%
Chronic kidney disease 27%
Diabetes 26%
Ischemic heart disease 26%
Depression 22%
COPD 21%
Osteoporosis 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $524
$524 — —
TAVNEOS
  • Amgen Inc. $216
$216 — —
SKYRIZI
  • AbbVie, Inc. $176
$176 — —
TREMFYA
  • Janssen Biotech, Inc. $89
$89 — —
ORENCIA
  • E.R. Squibb & Sons, L.L.C. $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

136 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record